FDA Approves First CRISPR Gene Therapies for Sickle Cell Disease, Marking New Era in Medicine
In December 2023, the U.S. Food and Drug Administration (FDA) approved the first two cell-based gene therapies for sickle cell disease. One of these, exagamglogene autotemcel (exa-cel; Casgevy; Vertex Pharmaceuticals, CRISPR Therapeutics), is notable as the first FDA-approved therapy to utilize genome editing with clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9. This approval represents a significant advancement in medical treatment, moving beyond managing symptoms to directly intervening in the biology responsible for the disease. The treatment process for exa-cel involves stem cell collection and modification, conditioning chemotherapy, hospitalization, and recovery. While the process can be challenging for patients, as described by one Florida patient who experienced side effects like hair loss and mouth sores, the outcome has been transformative, with patients reporting a complete absence of pain. This development follows years of research and clinical...